Mn Services Vermogensbeheer B.V. Has $6.51 Million Stock Position in Illumina, Inc. (NASDAQ:ILMN)

Mn Services Vermogensbeheer B.V. reduced its position in Illumina, Inc. (NASDAQ:ILMN) by 2.8% during the 2nd quarter, according to the company in its most recent filing with the Securities and Exchange Commission (SEC). The fund owned 62,400 shares of the life sciences company’s stock after selling 1,800 shares during the period. Mn Services Vermogensbeheer B.V.’s holdings in Illumina were worth $6,513,000 at the end of the most recent quarter.

A number of other hedge funds and other institutional investors also recently made changes to their positions in ILMN. Vanguard Group Inc. increased its holdings in Illumina by 0.4% in the first quarter. Vanguard Group Inc. now owns 18,245,041 shares of the life sciences company’s stock worth $2,505,409,000 after buying an additional 66,528 shares during the last quarter. Edgewood Management LLC increased its stake in shares of Illumina by 4.6% during the 4th quarter. Edgewood Management LLC now owns 6,878,495 shares of the life sciences company’s stock worth $957,762,000 after purchasing an additional 302,222 shares during the last quarter. Baillie Gifford & Co. raised its holdings in shares of Illumina by 8.7% during the 1st quarter. Baillie Gifford & Co. now owns 5,736,418 shares of the life sciences company’s stock valued at $787,725,000 after purchasing an additional 460,649 shares in the last quarter. WCM Investment Management LLC lifted its stake in shares of Illumina by 2,232.3% in the 1st quarter. WCM Investment Management LLC now owns 3,377,221 shares of the life sciences company’s stock valued at $463,760,000 after purchasing an additional 3,232,418 shares during the last quarter. Finally, Capital World Investors boosted its holdings in Illumina by 41.1% in the first quarter. Capital World Investors now owns 2,753,504 shares of the life sciences company’s stock worth $378,111,000 after purchasing an additional 801,814 shares in the last quarter. 89.42% of the stock is owned by hedge funds and other institutional investors.

Analysts Set New Price Targets

ILMN has been the topic of several recent research reports. Barclays upgraded Illumina from an “underweight” rating to an “equal weight” rating and set a $125.00 target price on the stock in a report on Wednesday, August 14th. StockNews.com assumed coverage on Illumina in a report on Wednesday. They issued a “buy” rating for the company. Jefferies Financial Group assumed coverage on Illumina in a research report on Monday, June 3rd. They set a “hold” rating and a $115.00 target price for the company. Daiwa America raised shares of Illumina to a “strong-buy” rating in a research report on Friday, August 16th. Finally, Daiwa Capital Markets raised shares of Illumina from a “neutral” rating to a “buy” rating and upped their price objective for the stock from $120.00 to $154.00 in a report on Friday, August 16th. One investment analyst has rated the stock with a sell rating, nine have assigned a hold rating, twelve have assigned a buy rating and one has given a strong buy rating to the stock. According to MarketBeat, the company currently has an average rating of “Moderate Buy” and an average price target of $151.10.

Illumina Stock Performance

Shares of ILMN traded up $2.06 on Friday, reaching $131.39. 832,032 shares of the stock traded hands, compared to its average volume of 2,107,289. The stock’s 50-day moving average price is $116.94 and its 200-day moving average price is $121.97. The company has a debt-to-equity ratio of 0.26, a current ratio of 1.75 and a quick ratio of 1.36. The firm has a market cap of $20.93 billion, a price-to-earnings ratio of -16.12 and a beta of 1.15. Illumina, Inc. has a 12 month low of $89.00 and a 12 month high of $171.50.

Illumina (NASDAQ:ILMN) last announced its quarterly earnings results on Tuesday, August 6th. The life sciences company reported $0.36 earnings per share (EPS) for the quarter, beating the consensus estimate of $0.12 by $0.24. The firm had revenue of $1.11 billion for the quarter, compared to analyst estimates of $1.09 billion. Illumina had a negative net margin of 28.71% and a positive return on equity of 2.31%. The business’s revenue for the quarter was down 5.4% on a year-over-year basis. During the same quarter in the previous year, the firm posted $0.32 EPS. Equities analysts forecast that Illumina, Inc. will post 1.5 EPS for the current fiscal year.

Illumina Profile

Illumina, Inc offers sequencing- and array-based solutions for genetic and genomic analysis in the United States, Singapore, the United Kingdom, and internationally. It operates through Core Illumina and GRAIL segments. The company offers sequencing and array-based instruments and consumables, which include reagents, flow cells, and library preparation; whole-genome sequencing kits, which sequence entire genomes of various size and complexity; and targeted resequencing kits, which sequence exomes, specific genes, and RNA or other genomic regions of interest.